Yoichi Ozawa

Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway

Yu Kato, Kimiyo Tabata, Takayuki Kimura et al. · PLoS ONE · 2019 · 463 citations · Full text

Life Sciences, Immunology, Oncology +17

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states

Takeshi Yoshida, Yoichi Ozawa, Takayuki Kimura et al. · British Journal of Cancer · 2014 · 357 citations · Full text

Medicine, Cancer Biology, Oncology +17

Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model

Takayuki Kimura, Yu Kato, Yoichi Ozawa et al. · Cancer Science · 2018 · 342 citations · Full text

Medicine, Oncology, Pharmacology +17

Discovery of Novel Antitumor Sulfonamides Targeting G1 Phase of the Cell Cycle

Takashi Owa, Hiroshi Yoshino, Tatsuo Okauchi et al. · Journal of Medicinal Chemistry · 1999 · 325 citations

Medicine, Oncology, Pharmacology +13

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models

Yasuhiro Funahashi, Kiyoshi Okamoto, Yusuke Adachi et al. · Cancer Science · 2014 · 278 citations · Full text

Medicine, Oncology, Pharmacology +17